CD274 and neoplasm: In GLOW and SPOTLIGHT, the overlap of CLDN18.2 and PD-L1 tumor expression was evaluated as an ad hoc analysis in a subset of randomized patients; in GLOW, 21.9% of assessed patients had tumors with a PD-L1 CPS ≥5, and, in SPOTLIGHT, 13.2% of assessed patients had tumors with a PD-L1 CPS ≥5 (ref. 28).